Jain N, Zhao Z, Feucht J, Koche R, Iyer A, Dobrin A, Mansilla-Soto J, Yang J, Zhan Y, Lopez M, Gunset G, Sadelain M. 2023. TET2 guards against unchecked BATF3-induced CAR T cell expansion. Nature 10.1038/s41586-022-05692-z
Odak A, Yuan H, Feucht J, Cantu VA, Mansilla-Soto J, Kogel F, Eyquem J, Everett JK, Bushman FD, Leslie C, Sadelain M. 2023. Novel extragenic genomic safe harbors for precise therapeutic T cell engineering. Blood 10.1182/blood.2022018924
Amor C, Feucht J, Leibold J, Ho YJ, Zhu C, Alonso-Curbelo D, Mansilla-Soto J, Boyer JA, Li X, Giavridis T, Kulick A, Houlihan S, Peerschke E, Friedman SL, Ponomarev V, Piersigilli A, Sadelain M, Lowe SW. 2020. Senolytic CAR T cells reverse senescence-associated pathologies. Nature 583:127-32. doi:10.1038/s41586-020-2403-9
Feucht J, Sun J, Eyquem J, Ho YJ, Zhao Z, Leibold J, Dobrin A, Cabriolu A, Hamieh M, Sadelain M. 2019. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med 25:82-8. doi:10.1038/s41591-018-0290-5
Mansilla-Soto J, Eyquem J, Haubner S, Hamieh M, Feucht J, Paillon N, Zucchetti AE, Li Z, Sjostrand M, Lindenbergh PL, Saetersmoen M, Dobrin A, Maurin M, Iyer A, Garcia Angus A, Miele MM, Zhao Z, Giavridis T, van der Stegen SJC, Tamzalit F, Riviere I, Huse M, Hendrickson RC, Hivroz C, Sadelain M. 2022. HLA-independent T cell receptors for targeting tumors with low antigen density. Nat Med 28:345-52. doi:10.1038/s41591-021-01621-1
Feucht J, Sadelain M. 2020. Function and evolution of the prototypic CD28zeta and 4-1BBzeta chimeric antigen receptors. Immunooncol Technol 8:2-11. doi:10.1016/j.iotech.2020.09.001